NCT00794287

Brief Summary

To determine which subclass of IgG in the serum of patients undergoing SIT against wasp venom is able to neutralize the allergen, and therefore to prevent a positive CAST

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 19, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 20, 2008

Completed
1 month until next milestone

Study Start

First participant enrolled

January 1, 2009

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Last Updated

June 4, 2015

Status Verified

June 1, 2015

Enrollment Period

1.9 years

First QC Date

November 19, 2008

Last Update Submit

June 3, 2015

Conditions

Wasp Venom Allergic Patients

Study Arms (2)

1

Hymenoptera allergic patients before allergen specific immunotherapy

Other: Taking blood samples

2

Hymenoptera allergic patients after allergen specific immunotherapy

Other: Taking blood samples

Interventions

Taking blood samplesOTHER

No intervention is done. Only blood samples are taken.

12

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Wasp venom allergic patients grade III and IV according to H.L. Müller in the age group of 18-75 years

You may qualify if:

  • male and female patient with allergy to wasp venom grade III and IV according to H.L. Müller
  • years
  • planned SIT against wasp venom or finished 5 years SIT against wsp venom (10/10)

You may not qualify if:

  • oral corticosteroids
  • chromogycin
  • ketotifen
  • immunosuppressive drugs within the last 2 years

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Zurich, Switzerland

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood samples

Study Officials

  • 01 Studienregister MasterAdmins

    UniversitaetsSpital Zuerich

    STUDY DIRECTOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 19, 2008

First Posted

November 20, 2008

Study Start

January 1, 2009

Primary Completion

December 1, 2010

Last Updated

June 4, 2015

Record last verified: 2015-06

Locations

CH(1)